EUVIMEDEUVIMED entdecken
Crossref

Precision medicine for somatic mutation-driven vascular anomalies

Yulang Xu iD, Jiangyuan Zhou, Yuru Lan, Yi Ji

British Journal of Dermatology · 17.09.2026

DOI: 10.1093/bjd/ljag409 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 17.09.2026. Verfasst von Yulang Xu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Pediatric Surgery, and Rare Diseases Center, West China Hospital, Sichuan University, the People's Republic of Ch…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 171 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Excellent Youth Foundation of Sichuan Province of China, Natural Science Foundation of Sichuan Province of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular anomalies, including proliferative vascular tumours and structural malformations, are largely driven by postzygotic somatic mutations that constitutively activate key signalling pathways, mainly the phosphoinositide 3-kinase (PI3 K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) and RAS/mitogen activated protein kinase (MAPK) pathways. This molecular understanding has shifted clinical management from empiric interventions towards precision medicine. In this review, the interactions between somatic mosaicism, germline predispositions (e.g. phosphatase and tensin homologue hamartoma tumour syndrome) and microenvironmental risk factors in the context of lesional progression are described. We synthesized data on genotype‒phenotype correlations, such as PIK3CA mutations in lymphatic and venous malformations, KRAS/MAP2K1 mutations in arteriovenous malformations and cerebral cavernous malformation complex dysfunctions in cerebral cavernous anomalies, while fundamentally differentiating the mechanistic dependencies of true malformations from those of proliferative tumours. Targeted therapies, including mTOR, PI3Kα and MEK inhibitors, have exhibited significant clinical efficacy in the treatment of pathway-specific anomalies. Despite these advances, therapeutic resistance and drug dependency persist. Future directions include the development of integrated diagnostic frameworks combining tissue biopsies with longitudinal cell-free DNA monitoring, optimizing dual-pathway combination strategies and advancing cellular models to reshape the management of vascular anomalies.

Autor:innen und Institutionen

  • Division of Oncology, Department of Pediatric Surgery, and Rare Diseases Center, West China Hospital, Sichuan University, the People's Republic of China.

ORCID-Profile: Yulang Xu

Förderung

  • National Natural Science Foundation of China
  • Excellent Youth Foundation of Sichuan Province of China
  • Natural Science Foundation of Sichuan Province of China
  • West China Hospital of Sichuan University
  • Sichuan University
  • Med-X Center for Informatics

Zitieren

APA

Xu, Y., Zhou, J., Lan, Y., & Ji, Y. (2026). Precision medicine for somatic mutation-driven vascular anomalies. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljag409

Vancouver

Xu Y, Zhou J, Lan Y, Ji Y. Precision medicine for somatic mutation-driven vascular anomalies. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljag409

BibTeX
@article{Xu2026,
  author = {Xu, Yulang and Zhou, Jiangyuan and Lan, Yuru and Ji, Yi},
  title = {Precision medicine for somatic mutation-driven vascular anomalies},
  journal = {British Journal of Dermatology},
  year = {2026},
  doi = {10.1093/bjd/ljag409}
}
Kostenlos starten →